Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 376 clinical trials
MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

To compare the efficacy of Medroxyprogesterone Acetate with dydrogesterone in patients having endometrial hyperplasia (EH) without atypia.

  • 0 views
  • 25 Jan, 2021
  • 1 location
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

interleukin-2 works in treating patients with metastatic kidney cancer.

cervical carcinoma in situ
carcinoma in situ
hypertension
metastatic renal cell carcinoma
carcinoma
  • 17 views
  • 07 Nov, 2020
  • 2 locations
  • 0 views
  • 25 Jan, 2021
  • 26 locations
Ketogenic Diet for Patients Receiving First Line Treatment for Metastatic Renal Cell Carcinoma

The purpose of this study is to evaluate the tolerance of one year of ketogenic diet associated with vitamin supplementation in patients treated for a metastatic renal cell carcinoma.

  • 0 views
  • 26 Jan, 2021
  • 1 location
A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients

active to warrant further investigation in randomized phase II or III studies. Metastatic renal cell cancer (mRCC) patients with PD-1 expressing immune cells are more likely to have larger more

  • 0 views
  • 26 Jan, 2021
  • 3 locations
Bevacizumab in Advanced Hepatocellular Carcinoma

liver cancer. Bevacizumab is an angiogenesis inhibitor already successfully used in patients with colorectal and renal cancers.

angiogenesis inhibitor
alpha fetoprotein
cirrhosis
cancer
neutrophil count
  • 14 views
  • 07 Nov, 2020
  • 1 location
Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

Combination treatment of Durvalumab with chemoradiotherapy is ongoing for head/neck cancer, renal cell carcinoma, melanoma, and non-small cell lung cancer (NCT02318771) and pancreatic cancer

  • 0 views
  • 23 Jan, 2021
  • 1 location
Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma

molecule multi-kinase inhibitor of VEGFR, PDGFR and RAF with demonstrated activity in the treatment of renal cell cancer (9). Preclinical studies suggest that the combination of Sorafenib with

measurable disease
ifosfamide
immunomodulators
anthracyclines
soft tissue sarcoma
  • 13 views
  • 07 Nov, 2020
  • 1 location
Molecular Determinants for Therapy Response on Renal Cell Carcinoma

Aim of the scientific analysis is to find biological factors (biomarkers) allowing a prediction of disease progression and a better choice of therapy. After diagnosis the kidney and the tumor will be removed by standard surgery followed by drug therapy. Within surgery remaining tumor tissue will be used for the …

biological factors
everolimus
systemic therapy
sunitinib
pazopanib
  • 28 views
  • 08 Nov, 2020
A Phase 1 Study of HLX20 a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors

This is an open-label, dose escalation, first-in-human study of HLX20, an anti-PD-L1 monoclonal antibody, in patients with metastatic or recurrent solid tumors who have failed standard therapy.

  • 47 views
  • 22 Jan, 2021
  • 5 locations